Venlafaxine serum levels and CYP2D6 genotype

Therapeutic Drug Monitoring

Volumn 22, Issue 2, 2000, Pages 202-208

  Veefkind, Adrian H ^a   Haffmans, P M Judith ^b   Hoencamp, Erik ^b  

^a Psychiatric Center Zon and Schild   (Netherlands)

^b PARNASSIA PSYCHIATRIC INSTITUTE   (Netherlands)

Author keywords

CYP2D6; Plasma concentrations; Poor metabolizers; Ultrarapid metabolizers; Venlafaxine

Indexed keywords

DEBRISOQUINE 4 HYDROXYLASE; DESVENLAFAXINE; N DESMETHYLVENLAFAXINE; UNCLASSIFIED DRUG; VENLAFAXINE;

ARTICLE; DEPRESSION; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SPECIFICITY; ENZYME BINDING; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; CYTOCHROME P-450 CYP2D6; GENOTYPE; HUMANS;

EID: 0034108957     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200004000-00011     Document Type: Article

References (18)

1. Morton WA, Sonnqe SC, Verga MA. Venlafaxine: a structurally unique and novel antidepressant. Ann Pharmacother 1995;29:387-95.
2. Muth EA, Haskins JT, Moyer JA, Husbands GEM, Nielsen ST, Sigg EB. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986;35:4493-7.
3. Holliday SM, Benfield P, Venlafaxine: A review of its pharmacology and therapeutic potential in depression. Drugs 1995;49: 280-94.
4. Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996;41:149-156.
5. Richelson E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc 1997;72: 835-847.
6. Hoencamp E, Haffmans PMJ, Dijken WA, Huijbrechts IPAM. Lithium augmentation of venlafaxine: open-label trial. J Clin Psychopharmacol 2000; accepted for publication.
7. Daly AK, Brockmöller J, Broly F et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996;6:193-201.
8. Heim M, Meyer UA. Genotyping of poor metabolizers of debrisoquine by allele-specific amplification. Lancet 1990;336:529-532.
9. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997;60:284-95.
10. Gough AC, Miles JS, Spurr NK, et al. Identification of the primary gene defect at the cytochrome P450 CYP2D6 locus. Nature 1990; 347:773-6.
11. Steijns LSW, Weide J van der. Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication. Clin Chem 1998;44: 914-917.
12. Hicks DR, Wolaniuk D, Russell A, Cavanaugh N, Kraml M. A high-performance liquid chromatographic method for the simultaneous determination of venlafaxine and O-desmethylvenlafaxine in biological fluids. Ther Drug Monit 1994;16:100-107.
13. Siegel S, Castellan NJ Jr. Nonparametric statistics for behavioral sciences. 2nd ed. Singapore: McGraw-Hill International Editions; 1988:206-216.
14. Data on file, Medical Affairs Department Wyeth Ayerst International Inc. (600A-313-US).
15. Meyer UA, Amrein R, Balant LP et al. Antidepressants and drug-metabolizing enzymes - expert group report. Acta Psychiatr Scand 1996;93:71-9.
16. Dahl M-L, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995;274:516-20.
17. Bertilsson L, Dahl M-L , Sjöqvist F et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 1993;341:63.
18. Dahl M-L, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995;274:516-20.